STACCATO | European Industrial Doctorate for enhancing upstream biopharmaceutical manufacturing process development through single cell analysis

Summary
Our ability to utilise biological systems to produce medicines has improved the quality of life for millions of EU citizens. In recent years a new wave of exciting biopharmaceuticals have been discovered with the potential to advance current treatments for a variety of disorders. These new medicines, however, are becoming increasingly complex and difficult to manufacture. Overcoming the inherent heterogeneity of cells grown in vitro to produce effective, uniform and safe biopharmaceuticals is one of the most significant challenges faced by industry today.
The STACCATO European Industrial Doctorate has been specifically designed to strengthen Europe’s innovation capacity and leadership in the BioPharma sector. The consortium will provide exceptional intersectoral training to 11 ESRs through pioneering research focused on harnessing recent advances in single cell analysis to generate and apply a new suite of tools for cell culture process development. ESRs will participate in a specialised training programme to build their proficiency in essential research and industry disciplines. Additional training in professional skills and entrepreneurship will enable ESRs to become future leaders in biopharmaceutical manufacturing science.
STACCATO is composed of an industry leader in instrumentation for cellular analysis, 3 innovative biotechnology SMEs, a leading academic institution and a research conducting biological medicines regulatory agency. The STACCATO EID will immerse all ESRs in highly dynamic industrial environments while receiving supervision from leading academics. A feature of STACCATO is collaboration amongst experts in the production of different biopharmaceuticals such as therapeutic proteins and CAR T cell therapy. All ESRs will receive unparalleled exposure to pan-biopharmaceutical manufacturing challenges to foster collaboration, catalyse synergies across the network and ultimately create a truly unique training experience.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/813453
Start date: 01-01-2019
End date: 31-12-2022
Total budget - Public funding: 2 924 526,24 Euro - 2 924 526,00 Euro
Cordis data

Original description

Our ability to utilise biological systems to produce medicines has improved the quality of life for millions of EU citizens. In recent years a new wave of exciting biopharmaceuticals have been discovered with the potential to advance current treatments for a variety of disorders. These new medicines, however, are becoming increasingly complex and difficult to manufacture. Overcoming the inherent heterogeneity of cells grown in vitro to produce effective, uniform and safe biopharmaceuticals is one of the most significant challenges faced by industry today.
The STACCATO European Industrial Doctorate has been specifically designed to strengthen Europe’s innovation capacity and leadership in the BioPharma sector. The consortium will provide exceptional intersectoral training to 11 ESRs through pioneering research focused on harnessing recent advances in single cell analysis to generate and apply a new suite of tools for cell culture process development. ESRs will participate in a specialised training programme to build their proficiency in essential research and industry disciplines. Additional training in professional skills and entrepreneurship will enable ESRs to become future leaders in biopharmaceutical manufacturing science.
STACCATO is composed of an industry leader in instrumentation for cellular analysis, 3 innovative biotechnology SMEs, a leading academic institution and a research conducting biological medicines regulatory agency. The STACCATO EID will immerse all ESRs in highly dynamic industrial environments while receiving supervision from leading academics. A feature of STACCATO is collaboration amongst experts in the production of different biopharmaceuticals such as therapeutic proteins and CAR T cell therapy. All ESRs will receive unparalleled exposure to pan-biopharmaceutical manufacturing challenges to foster collaboration, catalyse synergies across the network and ultimately create a truly unique training experience.

Status

CLOSED

Call topic

MSCA-ITN-2018

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.1. Fostering new skills by means of excellent initial training of researchers
H2020-MSCA-ITN-2018
MSCA-ITN-2018